title: Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
abstract: BACKGROUND
  Nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are major causes of gastric mucosal lesions. In Japan, histamine-2 receptor antagonists are frequently prescribed, but the literature regarding their efficacy is limited. In this study, we compare the effects of famotidine and rebamipide on NSAID-associated gastric mucosal lesions using upper gastrointestinal endoscopy.
  
  
  METHODS
  This study examined 112 patients taking NSAIDs for either gastric hemorrhage or erosion. Before treatment, the patients were assessed by endoscopy. Using blind randomization, patients were divided into two groups: group F (famotidine, 20 mg/day) and group R (rebamipide, 300 mg/day). Efficacy was examined 4 weeks later using endoscopy.
  
  
  RESULTS
  After treatment, the Lanza score decreased significantly in group F (P < 0.001) but not in group R (P = 0.478). The change in the Lanza score in group F was significantly greater (P = 0.002) than that in group R.
  
  
  CONCLUSIONS
  Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions.
authors.affiliation: Third Department of Internal Medicine, Nara Medical University, 840 Shijocho, Kashihara 634-8512, Japan.
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Yamao
authors.forename: Eiryo
authors.initials: E
authors.lastname: Kikuchi
authors.forename: Masami
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Nakayama
authors.forename: Tatsuichi
authors.initials: T
authors.lastname: Ann
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kojima
authors.forename: Akira
authors.initials: A
authors.lastname: Mitoro
authors.forename: Motoyuki
authors.initials: M
authors.lastname: Yoshida
authors.forename: Masaaki
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yajima
authors.forename: Yoshizumi
authors.initials: Y
authors.lastname: Miyauchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ono
authors.forename: Koichi
authors.initials: K
authors.lastname: Akiyama
authors.forename: Goro
authors.initials: G
authors.lastname: Sakurai
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Ken
authors.initials: K
authors.lastname: Haruma
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Takakura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fukui
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016099:Endoscopy, Gastrointestinal; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; D015738:Famotidine; C052785:rebamipide; D000409:Alanine